GCM
HUMA icon

Graham Capital Management’s Humacyte HUMA Stock Holding History

Graham Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,635
Closed -$178K – 1342
2024
Q3 		$178K Buy
+32,635
New +$215K ﹤0.01% 939

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Management's HUMA Position: Q4 2024 in Review

Graham Capital Management sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 32,635 shares — an estimated $178K sold.

Graham Capital Management first reported a position in HUMA in Q3 2024 and held it in 1 quarter. The position peaked at $178K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • Graham Capital Management reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • Graham Capital Management sold 32,635 Humacyte shares in Q4 2024, an estimated $178K.
  • Graham Capital Management first reported a position in Humacyte in Q3 2024 and held it in 1 quarter.
  • Graham Capital Management's Humacyte position peaked at $178K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on Graham Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.